Incidence of unexpected leiomyosarcoma in a Turkish province: a retrospective multi-centre study in a low income setting

dc.contributor.authorTasdemir, Umit
dc.contributor.authorCeran, Mehmet Ufuk
dc.contributor.authorDirican, Aylin Onder
dc.contributor.authorAkar, Serra
dc.contributor.authorCelik, Cetin
dc.contributor.authorEnergin, Hasan
dc.contributor.authorGorkemli, Huseyin
dc.contributor.authorMammadova, Narmin
dc.contributor.authorColak, Eser
dc.contributor.authorAyhan, Ali
dc.contributor.orcID0000-0003-1923-2373en_US
dc.contributor.orcID0000-0002-8184-7531en_US
dc.contributor.pubmedID35253591en_US
dc.date.accessioned2022-11-18T11:44:19Z
dc.date.available2022-11-18T11:44:19Z
dc.date.issued2022
dc.description.abstractThe aim of the current study was to estimate the incidence of unexpected leiomyosarcoma (LMS) in patients who underwent surgery due to leiomyomas in Konya province, and to contribute to the literature discussing comparisons with similar studies. The digital archives of eight high-volume hospitals were studied for surgeries performed due to leiomyomas between January 2012 and January 2019, and leiomyosarcoma incidence was calculated based on the data obtained. Twenty-one patients in 3703 cases were found to have unexpected leiomyosarcoma, which means we can expect one leiomyosarcoma in 176 (0.56%) surgeries. Six more malignant tumours were detected among the remaining cases. Thus, our study estimated the incidence of unexpected leiomyosarcoma as 1/176 (0.56%), which is higher than most of the studies in the literature justifying the debate started by the FDA in 2014. As the tumour biology is not yet clear, and the incidence of unexpected leiomyosarcoma tends to be so high, the key focus must be to try to detect uterine leiomyosarcomas preoperatively for robust patient care.IMPACT STATEMENT What is already known on this subject? The incidence of unexpected leiomyosarcoma varies widely from 1/498 to 1/8300 depending on the study method and the type of procedure, and there is still controversy, even after the FDA statement that led to a major restriction in laparoscopic surgeries due to concerns about inadvertent morcellation of leiomyosarcomas. What do the results of this study add? To the best of our knowledge, the current study found the highest incidence of unexpected leiomyosarcoma, and consequently a serious evaluation of all patients undergoing surgery due to leiomyomas preoperatively considering a leiomyosarcoma candidate is recommended. What are the implications of these findings for clinical practice and/or further research? Studies on tumour biology and novel markers must be supported for accurate preoperative diagnosis of leiomyosarcoma.en_US
dc.identifier.endpage2212en_US
dc.identifier.issn0144-3615en_US
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85126238244en_US
dc.identifier.startpage2208en_US
dc.identifier.urihttp://hdl.handle.net/11727/8131
dc.identifier.volume42en_US
dc.identifier.wos000765612800001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1080/01443615.2022.2036958en_US
dc.relation.journalJOURNAL OF OBSTETRICS AND GYNAECOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectUnexpected leiomyosarcomaen_US
dc.subjectincidenceen_US
dc.subjecthysterectomyen_US
dc.subjectmyomectomyen_US
dc.subjectmorcellationen_US
dc.titleIncidence of unexpected leiomyosarcoma in a Turkish province: a retrospective multi-centre study in a low income settingen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: